



## Webcast Alert: Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders

May 23, 2018

CARLSBAD, Calif., May 23, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a general corporate update in conjunction with its 2018 Annual Meeting of Stockholders and Open House on Wednesday, May 23 at 2:10 p.m. Pacific Time (5:10 p.m. Eastern Time) in Carlsbad, CA.



A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, [www.ionispharma.com](http://www.ionispharma.com). A replay of the presentation will be available on the website within 48 hours and will be archived for a limited time.

If you plan to attend the meeting, please RSVP by visiting the "Investors & Media" page at [www.ionispharma.com](http://www.ionispharma.com).

### ABOUT IONIS PHARMACEUTICALS, INC.

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over 45 drugs in development. SPINRAZA<sup>®</sup> (nusinersen) has been approved in global markets for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) are two antisense drugs that Ionis discovered and successfully advanced through Phase 3 studies. TEGSEDI is under regulatory review for marketing approval in the U.S., EU and Canada for the treatment of patients with hereditary ATTR, or hATTR, amyloidosis. WAYLIVRA is under regulatory review for marketing approval in the U.S., EU and Canada for the treatment of patients with familial chylomicronemia syndrome, or FCS. WAYLIVRA is also in a Phase 3 study in patients with familial partial lipodystrophy, or FPL. Akcea, an affiliate of Ionis focused on developing and commercializing drugs to treat patients with serious and rare diseases, will commercialize TEGSEDI and WAYLIVRA, if approved. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at [www.ionispharma.com](http://www.ionispharma.com).

### IONIS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding the therapeutic and commercial potential of SPINRAZA, TEGSEDI (inotersen), WAYLIVRA (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' majority owned subsidiary. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2017, and most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals<sup>™</sup> is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics<sup>™</sup> is a trademark of Akcea Therapeutics, Inc. TEGSEDI<sup>™</sup> is a trademark of Akcea Therapeutics, Inc. WAYLIVRA<sup>™</sup> is a trademark of Akcea Therapeutics, Inc. SPINRAZA<sup>®</sup> is a registered trademark of Biogen.

 View original content with multimedia: <http://www.prnewswire.com/news-releases/webcast-alert-ionis-pharmaceuticals-provides-corporate-update-at-2018-annual-meeting-of-stockholders-300653162.html>

SOURCE Ionis Pharmaceuticals, Inc.

Investors, D. Wade Walke, Ph.D., Vice President, Investor Relations, Ionis Pharmaceuticals, 760-603-2741 or Media, Roslyn Patterson, Vice President, Corporate Communications, Ionis Pharmaceuticals, 760-603-2681